ConductScience.org, home

Paper803104

Expansion of the growth fraction in multiple myeloma with alkylating agents.

Salmon SE. Blood, 1975. Cited by 108 papers, by iCite.

Cite this record

ConductScience Library. Expansion of the growth fraction in multiple myeloma with alkylating agents. Papers, record 803104. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/803104

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Expansion of the growth fraction in multiple myeloma with alkylating agents.
PubMed
Journal
Blood
PubMed
Year
1975
PubMed
Publication types
Case Reports, Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
108
iCite
Relative citation ratio, by iCite
4.86
iCite
Revised in PubMed
2021-02-16
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Salmon SES E

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
MelphalanMajor topic
Multiple MyelomaMajor topic
VincristineMajor topic
Adult
Bone Marrow
Cell Count
DNA Replication
Humans
Kinetics
Male
Prednisone

Source PubMed

Download CSV of topics

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
CA-14087NCI NIH HHSUnited StatesPubMed
CA-14102NCI NIH HHSUnited StatesPubMed
NCI-C-73-7313NCPDCID CDC HHSUnited StatesPubMed

Source PubMed

Download CSV of grants

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 108 citations.

PMIDTitleJournalYearIn PapersSource
7764456Kinetic resistance to anticancer agents.Cytotechnology1993https://conductscience.org/library/papers/7764456PubMed
7006664Treatment comparisons in the third MRC myelomatosis trial. Medical Research Council's Working Party on Leukaemia in Adults.Br J Cancer1980https://conductscience.org/library/papers/7006664PubMed
6801866Hematologic disorders in the elderly.West J Med1981https://conductscience.org/library/papers/6801866PubMed
3896288Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults.Br J Cancer1985https://conductscience.org/library/papers/3896288PubMed
2347050Timed sequential chemotherapy following ifosfamide-induced kinetic recruitment in refractory ovarian cancer.Cancer Chemother Pharmacol1990https://conductscience.org/library/papers/2347050PubMed
1749301Interphase cell death as related to the cell cycle of melphalan-treated human myeloma cells.Med Oncol Tumor Pharmacother1991https://conductscience.org/library/papers/1749301PubMed
656862Progress in myeloma at last.Br Med J1978https://conductscience.org/library/papers/656862PubMed
302265Primary bioassay of human myeloma stem cells.J Clin Invest1977https://conductscience.org/library/papers/302265PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/803104

GET https://conductscience.org/api/papers/v1/803104/authors